01962nas a2200193   4500008004100000245014000041210006900181260000800250300001300258490000700271520124100278100002101519700002301540700001701563700001901580700001801599700001901617856013201636       2026                        eng d00aIntegrative transcriptomics and metabolomics reveal distinct metabolic reprogramming in luminal and triple-negative breast cancer cells0 aIntegrative transcriptomics and metabolomics reveal distinct met  cJAN  aaaiaf0030 v223 a<p>
	Breast cancer subtypes exhibit significant molecular and metabolic heterogeneity, influencing their aggressiveness and therapeutic responses. Among them, triple-negative breast cancer (TNBC) is highly aggressive and often resistant to conventional therapies. To investigate the metabolic programming of this aggressiveness, we conducted an integrated transcriptomics and metabolomics analysis comparing the MCF-7 (luminal A, ER+/PR+) and MDA-MB-231 (TNBC) breast cancer cell lines. Transcriptome analysis of MCF-7 and MDA-MB-231 revealed the differential expression of genes involved in key metabolic pathways. Metabolomics data, further corroborated by transcriptomics, suggest pathway enrichment in beta-alanine, histidine, glutathione, nucleotide metabolism, and the tricarboxylic acid cycle. MDA-MB-231 cells displayed a metabolically aggressive phenotype with enhanced oxidative phosphorylation, redox adaptation, and nucleotide turnover. In contrast, MCF-7 cells showed a more regulated amino acid and redox metabolism profile. The integration of transcriptomic and metabolite profiles highlighted potential metabolic vulnerabilities in TNBC, offering insights into subtype-specific differences at the molecular level.</p>
1 aRanawade, Preeti1 aSonwane, Babasaheb1 aBose, Ganesh1 aJadhav, Revati1 aJoshi, Rakesh1 aMittal, Smriti  uhttps://library.ncl.res.in/content/integrative-transcriptomics-and-metabolomics-reveal-distinct-metabolic-reprogramming-luminal